Linperlisib (a PI3Kδ inhibitor) plus chidamide (a histone deacetylase inhibitor) showed a 59.1% objective response rate in relapsed/refractory CTCL patients.
No dose-limiting toxic effects observed; treatment was generally well tolerated with manageable adverse events.
Median progression-free survival was 5.4 months, demonstrating meaningful disease control in a difficult-to-treat population.
All-oral regimen offers a convenient treatment option targeting complementary oncogenic pathways in advanced CTCL, particularly mycosis fungoides.
